Literature DB >> 12851762

Can spleen transplantation induce tolerance? A review of the literature.

Frank J M F Dor1, Bernd Gollackner, David K C Cooper.   

Abstract

In some rodent strain combinations, allogeneic spleen transplantation induces tolerance spontaneously to itself and to other donor-specific organs. In other combinations, a state of tolerance has been achieved in the weakened immune system of the recipient. The data indicate that if a balance can be achieved between host-versus-graft and graft-versus-host responses, tolerance develops, possibly due to the development of suppressor/regulatory cells. There have been a number of unsuccessful studies in outbred large animals, but none in MHC-defined donor-recipient pairs, and none in which the protocol specifically aimed at inducing tolerance. Spleen transplantation has been performed in approximately 50 humans for a number of reasons, however no clear immunologic advantage has been reported. Graft-versus-host disease (GVHD) was documented in at least 3 patients, and was lethal in one case, despite excision of the donor spleen. The advantages of tolerance over chronic immunosuppressive therapy are so great that a potentially tolerogenic approach such as spleen transplantation would seem worthy of further investigation in a suitable large animal model. Such a study is ongoing at our center.

Entities:  

Mesh:

Year:  2003        PMID: 12851762     DOI: 10.1007/s00147-003-0640-0

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  8 in total

1.  Immunologic benefits of spleen transplantation in the absence of graft-versus-host disease.

Authors:  Frank J M F Dor; David K C Cooper
Journal:  Ann Surg       Date:  2006-05       Impact factor: 12.969

2.  Correction of hemophilia as a proof of concept for treatment of monogenic diseases by fetal spleen transplantation.

Authors:  Anna Aronovich; Dalit Tchorsh; Helena Katchman; Smadar Eventov-Friedman; Elias Shezen; Uri Martinowitz; Bruce R Blazar; Sivan Cohen; Orna Tal; Yair Reisner
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-05       Impact factor: 11.205

3.  Histopathology of spleen allograft rejection in miniature swine.

Authors:  Frank J M F Dor; Bernd Gollackner; Kenji Kuwaki; Dicken S C Ko; David K C Cooper; Stuart L Houser
Journal:  Int J Exp Pathol       Date:  2005-02       Impact factor: 1.925

4.  Small spleen peptides prevent development of psoriatic arthritis via restoration of peripheral tolerance.

Authors:  Viktor Wixler; Igor Z Zaytsev; Rafael Leite Dantas; Tanja Schied; Yvonne Boergeling; Veronika Lührmann; Georg Varga; Dörthe Masemann; Stephan Ludwig
Journal:  Mol Ther       Date:  2021-08-25       Impact factor: 11.454

5.  Transplantation of the spleen: effect of splenic allograft in human multivisceral transplantation.

Authors:  Tomoaki Kato; Andreas G Tzakis; Gennaro Selvaggi; Jeffrey J Gaynor; Hidenori Takahashi; James Mathew; Rolando Garcia-Morales; Erick Hernandez; Andre David; Seigo Nishida; David Levi; Jang Moon; Eddie Island; Gary Kleiner; Phillip Ruiz
Journal:  Ann Surg       Date:  2007-09       Impact factor: 12.969

6.  A novel role for factor VIII and thrombin/PAR1 in regulating hematopoiesis and its interplay with the bone structure.

Authors:  Anna Aronovich; Yaniv Nur; Elias Shezen; Chava Rosen; Yael Zlotnikov Klionsky; Irit Milman; Liran Yarimi; David Hagin; Gidi Rechavi; Uriel Martinowitz; Takashi Nagasawa; Paul S Frenette; Dalit Tchorsh-Yutsis; Yair Reisner
Journal:  Blood       Date:  2013-08-27       Impact factor: 22.113

7.  Donor Recipient Chimeric Cells Induce Chimerism and Extend Survival of Vascularized Composite Allografts.

Authors:  Joanna Cwykiel; Arkadiusz Jundzill; Aleksandra Klimczak; Maria Madajka-Niemeyer; Maria Siemionow
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2021-05-10       Impact factor: 4.291

8.  Tolerance and lymphoid organ structure and function.

Authors:  Bryna E Burrell; Yaozhong Ding; Yumi Nakayama; Kyung-Su Park; Jiangnan Xu; Na Yin; Jonathan S Bromberg
Journal:  Front Immunol       Date:  2011-12-07       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.